This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
AtriCure (ATRC) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
AtriCure (ATRC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SurModics (SRDX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
SurModics (SRDX) delivered earnings and revenue surprises of 63.89% and 3.47%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Stryker (SYK) Q4 Earnings Lag Estimates
by Zacks Equity Research
Stryker (SYK) delivered earnings and revenue surprises of -0.37% and 1.93%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
AtriCure (ATRC) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
AtriCure (ATRC) delivered earnings and revenue surprises of 739.39% and 2.19%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate AtriCure (ATRC) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
AtriCure (ATRC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AtriCure (ATRC) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
AtriCure (ATRC) delivered earnings and revenue surprises of -9.09% and 15.91%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate AtriCure (ATRC) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
AtriCure (ATRC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AtriCure (ATRC) Soars 8.8%: Is Further Upside Left in the Stock?
by Zacks Equity Research
AtriCure (ATRC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
AtriCure (ATRC) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
AtriCure (ATRC) delivered earnings and revenue surprises of 7.32% and 5.39%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
AtriCure (ATRC) Looks Good: Stock Adds 5.1% in Session
by Zacks Equity Research
AtriCure (ATRC) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
AtriCure (ATRC) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
AtriCure (ATRC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
OrganiGram (OGI) Surges: Stock Moves 8.9% Higher
by Zacks Equity Research
OrganiGram (OGI) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
AtriCure (ATRC) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
AtriCure (ATRC) delivered earnings and revenue surprises of 67.65% and 13.69%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate AtriCure (ATRC) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
AtriCure (ATRC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AtriCure (ATRC) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
AtriCure (ATRC) delivered earnings and revenue surprises of 64.29% and 16.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate AtriCure (ATRC) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
AtriCure (ATRC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AtriCure (ATRC) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
AtriCure (ATRC) delivered earnings and revenue surprises of 5.26% and 0.27%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate AtriCure (ATRC) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
AtriCure (ATRC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AtriCure Enters Overbought Territory
by Zacks Equity Research
AtriCure has moved higher as of late, but there could definitely be trouble on the horizon for this company.
AtriCure (ATRC) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
AtriCure (ATRC) delivered earnings and revenue surprises of -17.86% and 1.90%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate AtriCure (ATRC) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
AtriCure (ATRC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AtriCure Gains Expanded Labeling for Atriclip, Braces LAA Arm
by Zacks Equity Research
AtriCure's (ATRC) AtriClip devices are currently the most widely implanted left atrial appendage management devices globally.
AtriCure (ATRC) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
AtriCure (ATRC) delivered earnings and revenue surprises of 5.56% and 2.31%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Will AtriCure (ATRC) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
AtriCure (ATRC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AtriCure (ATRC) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
AtriCure (ATRC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.